NCT04739774View on ClinicalTrials.gov

Investigation of the Effect of Inhibition of CYP3A4/5 by Itraconazole on the PK of CHF6001 (Tanimilast)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 22, 2021

Primary Completion Date

April 20, 2021

Study Completion Date

April 26, 2021

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

CHF6001 DPI

Single dose of CHF6001

DRUG

Itraconazole

Repeated doses of oral Itraconazole

Trial Locations (1)

2060

SGS Life Sciences - Clinical Pharmacology Unit Antwerpen, Antwerp

All Listed Sponsors

lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT04739774 - Investigation of the Effect of Inhibition of CYP3A4/5 by Itraconazole on the PK of CHF6001 (Tanimilast) | Biotech Hunter | Biotech Hunter